デフォルト表紙
市場調査レポート
商品コード
1279649

バイオエンジニアリングタンパク質医薬品の世界市場規模調査&予測、薬剤タイプ別疾患別、技術別、ドラッグデリバリー方法別、地域別分析、2022-2029年

Global Bioengineered protein drugs Market Size study & Forecast, by Drug Type by Disease, by Technology, by Drug Delivery Method and Regional Analysis, 2022-2029

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
バイオエンジニアリングタンパク質医薬品の世界市場規模調査&予測、薬剤タイプ別疾患別、技術別、ドラッグデリバリー方法別、地域別分析、2022-2029年
出版日: 2023年05月09日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

強力な治療用タンパク質として機能するバイオエンジニアリング・タンパク質は、すべての生物学的プロセスに不可欠な参加者として作成されています。

これらのユニークな医薬品は、その特異性、安全性、生物学的反応性、深刻な病気や怪我の治療における成功率から、製薬業界の関心を集めています。バイオエンジニアリングされたタンパク質から作られた薬は、生物学的プロセスや効果的な治療薬の開発において重要な役割を担っています。バイオエンジニアリングされたタンパク質から作られる薬には、ホルモン、ワクチン、サイトカイン、モノクローナル抗体など、さまざまな項目が含まれています。バイオエンジニアリングタンパク質医薬品市場は、がんや糖尿病など様々な疾病の増加や個別化医療の進展などの要因によって拡大しています。

国際がん研究機関(IARC)の推計によると、2018年のがんの新規発生件数は1,700万件、がん関連死亡件数は950万件で、2040年には2,750万件に増加すると推定されています。慢性疾患の中で最も成長速度が速いものひとつに糖尿病があります。ここ数十年で、その有病率は着実に増加しています。世界保健機関は、2021年までに糖尿病が全世界で5億3,700万人に達し、10人に1人が他の病態を発症すると予測しています。さらに、高齢で太っている集団は、慢性疾患を発症する可能性が高くなります。世界銀行グループの推計によると、2020年の世界の高齢者数は7億2,700万人で、今後30年間で3倍に増え、2050年には15億人に達すると言われています。また、この地域における創薬活動の活発化、ヘルスケア研究開発活動の活発化が、市場の成長を促しています。しかし、バイオエンジニアリングタンパク質医薬品のコストが高いため、2022年から2029年の予測期間を通じて市場成長を阻害しています。

バイオエンジニアリングタンパク質医薬品の世界市場調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、中南米、その他の地域です。北米は、ブランド製品の優位性とこの地域の疾患有病率の増加により、売上高で市場を独占しています。一方、アジア太平洋地域は、老年人口や対象人口の増加、製品開拓のための共同研究の増加、主要企業の地域的拡大、政府機関や非営利団体の市場参入などの要因から、予測期間中に最高のCAGRで成長すると予想されます。

本調査の目的は、近年におけるさまざまなセグメント&国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国の産業の質的・量的な側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や薬剤の種類に関する詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

  • マーケットスナップショット
  • 世界市場・セグメント別市場推計・予測、2019年~2029年
    • バイオエンジニアリングタンパク質医薬品市場、地域別、2019年~2029年
    • バイオエンジニアリングタンパク質医薬品市場:薬物タイプ別、2019年~2029年
    • バイオエンジニアリングタンパク質医薬品市場:疾患別、2019年~2029年
    • バイオエンジニアリングタンパク質医薬品市場:技術別、2019年~2029年
    • バイオエンジニアリングタンパク質医薬品市場:ドラッグデリバリー方法別、2019年~2029年
  • 主な動向
  • 調査手法
  • 調査の前提条件

第2章 バイオエンジニアリングタンパク質医薬品の世界市場定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 本調査の対象範囲
    • 産業の進化
  • 本調査の対象年
  • 通貨換算レート

第3章 バイオエンジニアリングタンパク質医薬品の世界市場力学

  • バイオエンジニアリングタンパク質医薬品市場の影響分析(2019年~2029年)
    • 市場促進要因
      • がんや糖尿病など様々な疾患の増加
      • 個別化医療の進展
    • 市場の課題
      • バイオエンジニアリングタンパク質医薬品の高コスト
    • 市場機会
      • 製剤化の進展

第4章 バイオエンジニアリングタンパク質医薬品の世界市場の産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォースモデルの未来的アプローチ(2019年~2029年)
  • PEST分析
    • 政治的
    • 経済的
    • 社会的
    • 技術的
  • トップ投資機会
  • 主要成功戦略
  • 業界専門家別展望
  • アナリストの結論・提言

第5章 リスクアセスメントCOVID-19の影響

  • COVID-19が業界に与える全体的な影響についてのアセスメント
  • COVID-19以前とCOVID-19以後の市場シナリオ

第6章 バイオエンジニアリングタンパク質医薬品の世界市場、薬物タイプ別

  • 市場スナップショット
  • バイオエンジニアリングタンパク質医薬品の世界市場:薬剤タイプ別、実績 - ポテンシャル分析
  • バイオエンジニアリングタンパク質医薬品の世界市場、薬剤タイプ別推定・予測2019-2029
  • バイオエンジニアリングタンパク質医薬品の市場、サブセグメント分析
    • 遺伝子組換えタンパク質医薬品
    • ペプチドホルモン
    • ワクチン
    • 治療用酵素
    • モノクローナル抗体
    • サイトカイン
    • その他

第7章 バイオエンジニアリングタンパク質医薬品の世界市場:疾患別

  • 市場スナップショット
  • バイオエンジニアリングタンパク質医薬品の世界市場:疾患別、実績 - ポテンシャル分析
  • バイオエンジニアリングタンパク質医薬品の世界市場、疾患別、推定・予測2019-2029
  • バイオエンジニアリングタンパク質医薬品の市場、サブセグメント分析
    • 糖尿病
    • がん
    • 皮膚疾患
    • 血液疾患
    • 心臓疾患
    • 神経変性疾患
    • その他

第8章 バイオエンジニアリングタンパク質医薬品の世界市場:技術別

  • 市場スナップショット
  • バイオエンジニアリングタンパク質医薬品の世界市場:技術別、実績、ポテンシャル分析
  • バイオエンジニアリングタンパク質医薬品の世界市場:技術別、推定・予測2019-2029
  • バイオエンジニアリングタンパク質医薬品の市場、サブセグメント別分析
    • 分画
    • バイオリアクターと微生物細胞発酵
    • 遺伝子工学
    • 遺伝子組換え生物
    • 製剤化
    • その他

第9章 バイオエンジニアリングタンパク質医薬品の世界市場:ドラッグデリバリー方式別

  • 市場スナップショット
  • バイオエンジニアリングタンパク質医薬品の世界市場:ドラッグデリバリー方法別、実績 - ポテンシャル分析
  • バイオエンジニアリングタンパク質医薬品の世界市場:ドラッグデリバリー方式別、推定・予測2019-2029
  • バイオエンジニアリングタンパク質医薬品の市場、サブセグメント分析
    • 従来の方法
    • 最近の研究別新規アプローチ

第10章 バイオエンジニアリングタンパク質医薬品の世界市場:地域別分析

  • バイオエンジニアリングタンパク質医薬品市場、地域別市場スナップショット
  • 北米
    • 米国
      • 薬剤タイプ別の推定・予測、2019年~2029年
      • 疾患別の推定・予測、2019年~2029年
      • 技術別の推定・予測、2019年~2029年
      • ドラッグデリバリー方法別の推定・予測、2019-2029年
    • カナダ
  • 欧州バイオエンジニアリングタンパク質医薬品市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のバイオエンジニアリングタンパク質医薬品市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカバイオエンジニアリングタンパク質医薬品市場スナップショット
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域
  • 世界のその他の地域

第11章 競合情報

  • 主要市場戦略
  • 企業プロファイル
    • Abbott Laboratories
      • 主要情報
      • 概要
      • 財務情報(データ提供可能な場合のみ)
      • 製品概要
      • 最近の開発状況
    • Amgen
    • Baxter Healthcare
    • Bayer Healthcare Pharmaceuticals
    • Eli Lilly And Co.
    • GlaxoSmithKline
    • Hoffman-la-Roche
    • Johnson And Johnson
    • Merck And Co. Inc.,
    • Fresenius Kabi USA

第12章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • バリデーション
    • 出版
  • 調査の特徴
  • 調査の前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Bioengineered protein drugs Market, report scope
  • TABLE 2. Global Bioengineered protein drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Bioengineered protein drugs Market estimates & forecasts by Drug Type 2019-2029 (USD Billion)
  • TABLE 4. Global Bioengineered protein drugs Market estimates & forecasts by Diseases 2019-2029 (USD Billion)
  • TABLE 5. Global Bioengineered protein drugs Market estimates & forecasts by Technology 2019-2029 (USD Billion)
  • TABLE 6. Global Bioengineered protein drugs Market estimates & forecasts by Drug Delivery Method 2019-2029 (USD Billion)
  • TABLE 7. Global Bioengineered protein drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Bioengineered protein drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Bioengineered protein drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Bioengineered protein drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Bioengineered protein drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Bioengineered protein drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Bioengineered protein drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Bioengineered protein drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Bioengineered protein drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. Global Bioengineered protein drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 18. U.S. Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. U.S. Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 21. Canada Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. Canada Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 24. UK Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. UK Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 27. Germany Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. Germany Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 30. France Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. France Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 33. Italy Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Italy Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 36. Spain Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. Spain Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 39. RoE Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. RoE Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 42. China Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. China Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 45. India Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. India Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 48. Japan Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. Japan Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 51. South Korea Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. South Korea Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 54. Australia Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. Australia Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. RoAPAC Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 60. Brazil Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Brazil Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 63. Mexico Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. Mexico Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 66. RoLA Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. RoLA Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Bioengineered protein drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 69. Row Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. Row Bioengineered protein drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 71. List of secondary sources, used in the study of global Bioengineered protein drugs Market
  • TABLE 72. List of primary sources, used in the study of global Bioengineered protein drugs Market
  • TABLE 73. Years considered for the study
  • TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Bioengineered protein drugs Market, research methodology
  • FIG 2. Global Bioengineered protein drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Bioengineered protein drugs Market, key trends 2021
  • FIG 5. Global Bioengineered protein drugs Market, growth prospects 2022-2029
  • FIG 6. Global Bioengineered protein drugs Market, porters 5 force model
  • FIG 7. Global Bioengineered protein drugs Market, pest analysis
  • FIG 8. Global Bioengineered protein drugs Market, value chain analysis
  • FIG 9. Global Bioengineered protein drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Bioengineered protein drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Bioengineered protein drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Bioengineered protein drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Bioengineered protein drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Bioengineered protein drugs Market, regional snapshot 2019 & 2029
  • FIG 15. North America Bioengineered protein drugs Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Bioengineered protein drugs Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Bioengineered protein drugs Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Bioengineered protein drugs Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Bioengineered protein drugs Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Bioengineered protein drugs Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Bioengineered proteins, which serve as potent therapeutic proteins, are created to be essential participants in all biological processes. These unique medications are attracting interest from the pharmaceutical industry due to their specificity, safety, bio reactivity, and success rate in treating serious illnesses and injuries. Drugs made from bioengineered proteins are key players in the biological process and the development of effective therapeutics. The medication made from bioengineered proteins contains a variety of items, including hormones, vaccines, cytokines, and monoclonal antibodies. The Bioengineered protein drugs market is expanding because of factors such as rising prevelance of various diseases such as cancer, diabetes and other diseases as well as rising development of personalized medicine.

Rising prevelance of cancer globally is fostering the market growth, , according to estimates from the International Agency for Research on Cancer (IARC), there were 17.0 million new instances of cancer and 9.5 million cancer-related deaths in 2018 and it is estimated increase to 27.5 million new cases by 2040. One of the chronic diseases with the quickest rate of growth is diabetes. In recent decades, its prevalence has steadily increased. The World Health Organization projects that by 2021, diabetes will affect 537 million individuals worldwide, with one in ten developing other forms of the disease. Moreover, populations that are elderly and fat are more likely to develop chronic diseases. The World Bank Group estimates that there were 727 million senior citizens worldwide in 2020, and that number will triple over the next three decades, reaching 1.5 billion by 2050. In addition, rising drug discovery activities, and rising healthcare research and development activities in the region is fostering the market growth. However, the high cost of Bioengineered protein drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bioengineered protein drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of branded products and the region's increasing disease prevalence. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

  • Abbott Laboratories
  • Amgen
  • Baxter Healthcare
  • Bayer Healthcare Pharmaceuticals
  • Eli Lilly And Co.
  • GlaxoSmithKline
  • Hoffman-la-Roche
  • Johnson And Johnson
  • Merck And Co. Inc.,
  • Fresenius Kabi USA

Recent Developments in the Market:

  • In April 2022, Satellite Bio introduces a fresh method for creating tissues using bioengineering. This company has expertise in synthetic biology, regenerative medicine, cell therapy, cell biology, and tissue engineering.
  • In January 2022, A new biotechnology company named Altos Laboratories was founded with the goal of deciphering the intricate biology underlying the cellular renewal programming.

Global Bioengineered protein drugs Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug Type, Diseases, Technology, Drug Delivery Methods, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Drug Typeofferings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Type:

  • Recombinant Protein Drugs
  • Peptide Hormones
  • Vaccines
  • Therapeutic Enzymes
  • Monoclonal Antibodies
  • Cytokines
  • Others

By Disease:

  • Diabetes
  • Cancer
  • Skin Diseases
  • Blood disorders
  • Heart Diseases
  • Neurodegenerative Diseases
  • Others

By Technology:

  • Fractionation
  • Bioreactors And Microbial Cell Fermentation
  • Genetic Engineering
  • Genetically Modified Organisms
  • Pharming
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Bioengineered protein drugs Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Bioengineered protein drugs Market, by Drug Type, 2019-2029 (USD Billion)
    • 1.2.3. Bioengineered protein drugs Market, by Diseases, 2019-2029 (USD Billion)
    • 1.2.4. Bioengineered protein drugs Market, by Technology, 2019-2029 (USD Billion)
    • 1.2.5. Bioengineered protein drugs Market, by Drug Delivery Method, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Bioengineered protein drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Bioengineered protein drugs Market Dynamics

  • 3.1. Bioengineered protein drugs Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevelance of various diseases such as cancer and diabetes
      • 3.1.1.2. Growing development of personalised medicine
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Bioengineered protein drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advancements in Formulation

Chapter 4. Global Bioengineered protein drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Bioengineered protein drugs Market, by Drug Type

  • 6.1. Market Snapshot
  • 6.2. Global Bioengineered protein drugs Market by Drug Type, Performance - Potential Analysis
  • 6.3. Global Bioengineered protein drugs Market Estimates & Forecasts by Drug Type 2019-2029 (USD Billion)
  • 6.4. Bioengineered protein drugs Market, Sub Segment Analysis
    • 6.4.1. Recombinant Protein Drugs
    • 6.4.2. Peptide Hormones
    • 6.4.3. Vaccines
    • 6.4.4. Therapeutic Enzymes
    • 6.4.5. Monoclonal Antibodies
    • 6.4.6. Cytokines
    • 6.4.7. Others

Chapter 7. Global Bioengineered protein drugs Market, by Diseases

  • 7.1. Market Snapshot
  • 7.2. Global Bioengineered protein drugs Market by Diseases, Performance - Potential Analysis
  • 7.3. Global Bioengineered protein drugs Market Estimates & Forecasts by Diseases 2019-2029 (USD Billion)
  • 7.4. Bioengineered protein drugs Market, Sub Segment Analysis
    • 7.4.1. Diabetes
    • 7.4.2. Cancer
    • 7.4.3. Skin Diseases
    • 7.4.4. Blood disorders
    • 7.4.5. Heart Diseases
    • 7.4.6. Neurodegenerative Diseases
    • 7.4.7. Others

Chapter 8. Global Bioengineered protein drugs Market, by Technology

  • 8.1. Market Snapshot
  • 8.2. Global Bioengineered protein drugs Market by Technology, Performance - Potential Analysis
  • 8.3. Global Bioengineered protein drugs Market Estimates & Forecasts by Technology 2019-2029 (USD Billion)
  • 8.4. Bioengineered protein drugs Market, Sub Segment Analysis
    • 8.4.1. Fractionation
    • 8.4.2. Bioreactors And Microbial Cell Fermentation
    • 8.4.3. Genetic Engineering
    • 8.4.4. Genetically Modified Organisms
    • 8.4.5. Pharming
    • 8.4.6. Others

Chapter 9. Global Bioengineered protein drugs Market, by Drug Delivery Method

  • 9.1. Market Snapshot
  • 9.2. Global Bioengineered protein drugs Market by Drug Delivery Method, Performance - Potential Analysis
  • 9.3. Global Bioengineered protein drugs Market Estimates & Forecasts by Drug Delivery Method 2019-2029 (USD Billion)
  • 9.4. Bioengineered protein drugs Market, Sub Segment Analysis
    • 9.4.1. Traditional Methods
    • 9.4.2. Novel approaches according to recent research

Chapter 10. Global Bioengineered protein drugs Market, Regional Analysis

  • 10.1. Bioengineered protein drugs Market, Regional Market Snapshot
  • 10.2. North America Bioengineered protein drugs Market
    • 10.2.1. U.S. Bioengineered protein drugs Market
      • 10.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
      • 10.2.1.2. Diseases breakdown estimates & forecasts, 2019-2029
      • 10.2.1.3. Technology breakdown estimates & forecasts, 2019-2029
      • 10.2.1.4. Drug Delivery Method breakdown estimates & forecasts, 2019-2029
    • 10.2.2. Canada Bioengineered protein drugs Market
  • 10.3. Europe Bioengineered protein drugs Market Snapshot
    • 10.3.1. U.K. Bioengineered protein drugs Market
    • 10.3.2. Germany Bioengineered protein drugs Market
    • 10.3.3. France Bioengineered protein drugs Market
    • 10.3.4. Spain Bioengineered protein drugs Market
    • 10.3.5. Italy Bioengineered protein drugs Market
    • 10.3.6. Rest of Europe Bioengineered protein drugs Market
  • 10.4. Asia-Pacific Bioengineered protein drugs Market Snapshot
    • 10.4.1. China Bioengineered protein drugs Market
    • 10.4.2. India Bioengineered protein drugs Market
    • 10.4.3. Japan Bioengineered protein drugs Market
    • 10.4.4. Australia Bioengineered protein drugs Market
    • 10.4.5. South Korea Bioengineered protein drugs Market
    • 10.4.6. Rest of Asia Pacific Bioengineered protein drugs Market
  • 10.5. Latin America Bioengineered protein drugs Market Snapshot
    • 10.5.1. Brazil Bioengineered protein drugs Market
    • 10.5.2. Mexico Bioengineered protein drugs Market
    • 10.5.3. Rest of Latin America Bioengineered protein drugs Market
  • 10.6. Rest of The World Bioengineered protein drugs Market

Chapter 11. Competitive Intelligence

  • 11.1. Top Market Strategies
  • 11.2. Company Profiles
    • 11.2.1. Abbott Laboratories
      • 11.2.1.1. Key Information
      • 11.2.1.2. Overview
      • 11.2.1.3. Financial (Subject to Data Availability)
      • 11.2.1.4. Product Summary
      • 11.2.1.5. Recent Developments
    • 11.2.2. Amgen
    • 11.2.3. Baxter Healthcare
    • 11.2.4. Bayer Healthcare Pharmaceuticals
    • 11.2.5. Eli Lilly And Co.
    • 11.2.6. GlaxoSmithKline
    • 11.2.7. Hoffman-la-Roche
    • 11.2.8. Johnson And Johnson
    • 11.2.9. Merck And Co. Inc.,
    • 11.2.10. Fresenius Kabi USA

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption